RETATRUTIDE

Retatrutide (RUO) | Triple GIP/GLP-1/Glucagon Agonist

Retatrutide is a premier 39-amino acid unimolecular peptide engineered for potent triple-agonist activity. By simultaneously targeting the Gastric Inhibitory Polypeptide (GIP), Glucagon-Like Peptide-1 (GLP-1), and Glucagon (GCG) receptors, this compound offers a multifaceted approach to metabolic signaling research.

Its unique structure features a C20 fatty diacid moiety that facilitates high-affinity albumin binding. This critical modification protects the peptide from enzymatic degradation and extends its biological half-life to approximately 6 days, making it an ideal candidate for longitudinal studies in obesity, Type 2 Diabetes (T2D), and hepatic steatosis research models.

Product Specifications

Chemical Identity & Structural Mechanism

Retatrutide integrates activity at the Glucagon Receptor (GCGR) alongside GIP and GLP-1 to create a "Triple Synergy" mechanism that fundamentally alters the energy balance equation.

• Structure-Activity Relationship (SAR): The peptide backbone is derived from GIP but explicitly modified to introduce targeted Glucagon activity. The attached C20 fatty acid moiety is the primary driver of its extended 6-day half-life, allowing for sustained metabolic observation.

• Tuned Potency: The molecule is engineered with a highly specific hierarchy of receptor potency: maximum affinity at GIP for lipid buffering, moderate affinity at GLP-1 for satiety induction, and carefully tuned affinity at Glucagon to drive thermogenesis and energy expenditure without inducing hyperglycemia.

Why Leading Labs Source Retatrutide from Profound Aminos

Successful research demands absolute consistency. Retatrutide is a complex, acylated peptide that degrades rapidly if mishandled. We safeguard your data integrity through rigorous operational standards.

• Lot-Specific Transparency: We eliminate the "black box" of reagent sourcing. Every vial includes a Certificate of Analysis (COA) explicitly confirming the presence of the critical C20 fatty acid side chain, alongside HPLC analysis verifying ≥99% purity.

• USA-Based Cold-Chain Logistics: Thermal stress causes hydrolysis of the acylated side chain. Our stock is strictly maintained at -20°C in our US-based facility. By shipping directly to your lab, we minimize thermal exposure so you receive a research-ready molecule, not a degraded byproduct.

• The "Triple G" Advantage: Unlike dual agonists, sourcing true triple-agonist Retatrutide unlocks the ability to study energy expenditure and massive hepatic defatting simultaneously, offering the highest Return on Investigation (ROI) in current metabolic modeling.

Retatrutide vs. Competitors

Research Context & Clinical Insights (2025–2026)

• Obesity & Osteoarthritis (TRIUMPH-4): Phase 3 trials released in December 2025 demonstrated a mean weight reduction of 28.7% at the 12 mg dose. Crucially, the cohort saw a 75.8% reduction in knee pain scores, indicating benefits extend well beyond weight loss into structural and inflammatory improvements.

• Type 2 Diabetes (TRANSCEND-T2D-1): Currently investigated under NCT06354660, this pivotal trial evaluates Retatrutide against a placebo in adults with inadequate glycemic control, aiming to replicate the unparalleled weight reductions observed in non-diabetic cohorts.

• Hepatic Health (MASLD): In Phase 2 substudies, >90% of subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) achieved normal liver fat levels (<5%), positioning this molecule as a leading candidate for reversing hepatic steatosis.

Regulatory & Compliance Status

• FDA Status: Investigational New Drug (IND) currently in Phase 3 clinical trials. Not FDA-approved.

• WADA Status: Prohibited under S2 (Peptide Hormones).

• Usage: Strictly for Laboratory Research Use Only (RUO).

Frequently Asked Questions

Why is Retatrutide considered the “Gold Standard” over Tirzepatide and Semaglutide for obesity research?

Retatrutide represents a paradigm shift from traditional treatment to "medical bariatrics." While Semaglutide peaks at ~15% weight loss and Tirzepatide at ~21%, Retatrutide has demonstrated a staggering 28.7% mean body weight reduction in Phase 3 trials. It offers the highest therapeutic ceiling currently available in pharmacotherapy.

Does Retatrutide offer distinct advantages for Type 2 Diabetes (T2D) modeling?

Absolutely. In T2D trials, it achieved the largest weight reduction ever reported in a diabetic population (~17% vs. the typical 13%), alongside HbA1c reductions of up to 2.0%. It is a superior candidate for studying the reversal of "diabesity" and restoring normoglycemia.

How does the "Triple Agonist" mechanism drive superior results?

The addition of the Glucagon (GCG) receptor is the blockbuster differentiator. While older GLP-1/GIP agonists strictly suppress energy intake, Retatrutide attacks obesity on two fronts: it lowers caloric intake while actively increasing energy expenditure (thermogenesis) via glucagon signaling, helping bypass traditional metabolic adaptation plateaus.

With potent Glucagon activity, is there a risk of hyperglycemia in research subjects?

This is a common misconception. Retatrutide utilizes a perfectly "tuned" potency ratio where the robust insulinotropic effects of GIP and GLP-1 fully counterbalance the glucagon component. Clinical data confirms improved glycemic control despite glucagon activation.

Is the molecule stable enough for long-duration preclinical trials?

Yes. The engineered C20 fatty diacid moiety promotes albumin binding, extending the half-life to approximately 6 days. This supports convenient weekly administration protocols, reducing variable stress on research subjects.

LABORATORY DISCLAIMER

Products sold by Profound Aminos are strictly for scientific research, in vitro testing, and laboratory experimentation. These products are not intended to be used as foods, drugs, or cosmetics. The introduction of these products into humans or animals is strictly prohibited. They must not be misbranded, misused, mislabeled, or used for any purpose other than authorized scientific investigation.

All products are sold as a lyophilized (freeze-dried) powder in sealed sterile vials and require reconstitution and standard laboratory equipment for proper handling. While packaging and labeling are matched closely to our website representations, minor deviations may occur.

Would you like me to tailor this enhanced copy further for a specific medium, such as a website product page, an email marketing campaign, or a downloadable technical data sheet?